CL2019000397A1 - Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491) - Google Patents

Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491)

Info

Publication number
CL2019000397A1
CL2019000397A1 CL2019000397A CL2019000397A CL2019000397A1 CL 2019000397 A1 CL2019000397 A1 CL 2019000397A1 CL 2019000397 A CL2019000397 A CL 2019000397A CL 2019000397 A CL2019000397 A CL 2019000397A CL 2019000397 A1 CL2019000397 A1 CL 2019000397A1
Authority
CL
Chile
Prior art keywords
cyanophenyl
chloro
pyrazol
carboxamide
pyrazole
Prior art date
Application number
CL2019000397A
Other languages
English (en)
Inventor
Ilpo Laitinen
Oskari Karjalainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55802393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000397(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of CL2019000397A1 publication Critical patent/CL2019000397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

PROCESO PARA PREPARAR EL COMPUESTO N-((S)-1-(3-(3-CLORO-4-CIANOFENIL).1H-PIRAZOL-1-IL)-PROPAN-2-IL)-5-(1-HIDROXIETIL)-1H-PIRAZOL-3-CARBOXAMIDA
CL2019000397A 2015-04-09 2019-02-14 Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491) CL2019000397A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20150111 2015-04-09

Publications (1)

Publication Number Publication Date
CL2019000397A1 true CL2019000397A1 (es) 2019-05-10

Family

ID=55802393

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017002491A CL2017002491A1 (es) 2015-04-09 2017-10-03 Proceso para la preparación de antagonistas del receptor andrógeno e intermediarios de los mismos
CL2019000397A CL2019000397A1 (es) 2015-04-09 2019-02-14 Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017002491A CL2017002491A1 (es) 2015-04-09 2017-10-03 Proceso para la preparación de antagonistas del receptor andrógeno e intermediarios de los mismos

Country Status (30)

Country Link
US (1) US10189789B2 (es)
EP (1) EP3280710B1 (es)
JP (1) JP6707560B2 (es)
KR (1) KR102628078B1 (es)
CN (1) CN107428695B (es)
AU (1) AU2016245278B2 (es)
BR (1) BR112017021636B1 (es)
CA (1) CA2980965C (es)
CL (2) CL2017002491A1 (es)
CO (1) CO2017010052A2 (es)
CY (1) CY1123105T1 (es)
DK (1) DK3280710T3 (es)
ES (1) ES2800828T3 (es)
HK (1) HK1250710A1 (es)
HR (1) HRP20200707T1 (es)
HU (1) HUE049144T2 (es)
IL (1) IL254629B (es)
LT (1) LT3280710T (es)
MX (1) MX2017012910A (es)
MY (1) MY185488A (es)
PE (1) PE20171738A1 (es)
PL (1) PL3280710T3 (es)
PT (1) PT3280710T (es)
RS (1) RS60184B1 (es)
RU (1) RU2719590C2 (es)
SG (1) SG11201707959VA (es)
SI (1) SI3280710T1 (es)
UA (1) UA120777C2 (es)
WO (1) WO2016162604A1 (es)
ZA (1) ZA201706671B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018387110B2 (en) * 2017-12-19 2023-02-23 Boehringer Ingelheim Vetmedica Gmbh Synthesis of the 1 :1 :1 co-crystal of 1 -cyano-2-(4-cyclopropyl-benzyl)-4-(beta-D-glucopyranos-1 -yl)-benzene, L-proline and water
US11236070B2 (en) 2019-05-16 2022-02-01 Novartis Ag Chemical process
JP2022539142A (ja) 2019-07-02 2022-09-07 オリオン コーポレーション ダロルタミドの医薬組成物
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
CN110483534B (zh) * 2019-07-23 2021-05-18 上海药明康德新药开发有限公司 一种(2,4,5,7-四氢吡喃并[3,4-c]吡唑-7-基)甲醇的制备方法
CN111116477B (zh) * 2019-12-27 2021-04-20 武汉九州钰民医药科技有限公司 多拉米胺的合成工艺
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
AU2021269870A1 (en) 2020-05-11 2023-01-19 Orion Corporation Method for the preparation of androgen receptor antagonists and intermediates thereof
CN113527208A (zh) * 2021-08-31 2021-10-22 江西金丰药业有限公司 一步法制备2-氯-4-（1h-吡唑-3-基）苯甲腈的方法
CN113861115A (zh) * 2021-09-10 2021-12-31 浙江师范大学 一种吡唑酰胺类衍生物及合成方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
BR112013026905B1 (pt) * 2011-04-21 2021-09-14 Orion Corporation Compostos de carboxamida moduladora do receptor de andrógeno e seu uso no tratamento e prevenção de câncer de próstata, bem como composições farmacêuticas compreendendo os ditos compostos
MX343688B (es) * 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.

Also Published As

Publication number Publication date
PE20171738A1 (es) 2017-12-04
LT3280710T (lt) 2020-04-10
BR112017021636A2 (pt) 2018-07-10
RU2017134662A (ru) 2019-04-04
CO2017010052A2 (es) 2018-01-05
RU2017134662A3 (es) 2019-07-25
EP3280710A1 (en) 2018-02-14
EP3280710B1 (en) 2020-02-26
NZ736463A (en) 2023-09-29
HUE049144T2 (hu) 2020-08-28
ES2800828T3 (es) 2021-01-04
MX2017012910A (es) 2018-01-15
IL254629A0 (en) 2017-11-30
CL2017002491A1 (es) 2018-03-23
CN107428695A (zh) 2017-12-01
SI3280710T1 (sl) 2020-04-30
JP6707560B2 (ja) 2020-06-10
IL254629B (en) 2019-12-31
CA2980965C (en) 2024-01-02
BR112017021636B1 (pt) 2023-01-24
US10189789B2 (en) 2019-01-29
CY1123105T1 (el) 2021-10-29
MY185488A (en) 2021-05-19
RS60184B1 (sr) 2020-06-30
KR102628078B1 (ko) 2024-01-25
JP2018516857A (ja) 2018-06-28
RU2719590C2 (ru) 2020-04-21
UA120777C2 (uk) 2020-02-10
ZA201706671B (en) 2018-12-19
HRP20200707T1 (hr) 2020-07-24
KR20170134734A (ko) 2017-12-06
AU2016245278B2 (en) 2020-04-16
PL3280710T3 (pl) 2020-07-13
CA2980965A1 (en) 2016-10-13
US20180099938A1 (en) 2018-04-12
WO2016162604A1 (en) 2016-10-13
PT3280710T (pt) 2020-05-08
SG11201707959VA (en) 2017-10-30
CN107428695B (zh) 2021-03-16
DK3280710T3 (da) 2020-05-04
HK1250710A1 (zh) 2019-01-11
AU2016245278A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
CL2019000397A1 (es) Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491)
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201790715A1 (ru) Новые соединения
CU24567B1 (es) Derivados de piridiniltriazol sustituidos con amida útiles para tratar enfermedades renales y cardiovasculares
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
MA49879A (fr) Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
EA201890522A1 (ru) Способ получения противогрибковых соединений
EA202091500A1 (ru) Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
EA201692521A1 (ru) Пиразольные соединения и их применение в качестве блокаторов кальциевых каналов т-типа
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MY192425A (en) Polymorphs
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos